AnalysisNews

CRL today

$339.77-$1.04 (-0.31%)close Nov 13, 2026

Trend

DailyUptrend (confirmed)

4 hourStrong Bearish

1 hourLeaning Bullish

15 minSymmetric Triangle

5 minConsolidating

Daily trend turns down below $288.43

Key levels

Resistance$379.63

Resistance$358.76

Support$333.30

Support$311.68

Latest news & SEC filings

AnalystNov 13, 2026Banca Akros raises Carel Industries rating to Buy

AnalystNov 13, 2026Intermonte raises price target for Carel Industries

DealNov 12, 2026Charles River Laboratories, Toxys Broaden Existing Partnership

AnalystNov 11, 2026TD Cowen lifts its target on Charles River Labs to $388, keeps Buy

AnalystNov 10, 2026Analyst praises Charles River Laboratories' $470 million acquisition as a smart fit

All CRL news →

About Charles River Laboratories

Charles River Laboratories is a non-clinical drug development partner that supplies research models, offers discovery and safety assessment services, and provides manufacturing support. It operates through three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. Its customers include drugmakers, biotech firms, contract research organizations, academic and medical institutions, government bodies, and chemical and consumer product companies. The company has operations across North America, Europe, and Asia.

Based on the company's 10-K filed Feb 18, 2026.

NYSE · Healthcare

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

$338.21-2.60 (-0.76%)
HOLDGrade: CRisk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
313.6329.2344.9360.5338.21Oct 13Oct 21Oct 29Nov 6
High342.58
Low333.04
Open342.18
Volume240K
Avg Vol1.12M
VWAP336.11
30d High376.10
30d Low298.00
30d Chg+8.83%
See full chart with real-time data

What Is the Price Target for CRL?

SEPT Low Target

$219.00

SEPT Mid Target

$340.00

SEPT High Target

$400.00

Analyst Consensus

$340.00

Current: $342.46Upside: -0.7%Confidence: 85%Method: Analyst Consensus

Is CRL a Buy or Sell Right Now?

38
Investability Score
HOLD12-18 months
News summary · last 30 days
Nov 4▲ UpEarnings6 articles
Charles River Laboratories reported third-quarter 2026 adjusted earnings of $3.09 per share and revenue of $982.732 million, both beating analyst estimates of $2.97 and $958.693 million, and raised its full-year 2026 adjusted EPS guidance to $11.35-$11.55 and sales to $3.940B-$3.960B, above consensus. The company also lifted its FY2026 GAAP EPS outlook to $8.15-$8.35 from $3.05-$3.35. Despite the positive results and guidance, the stock closed at $326.29, down 6.75% from the open of $349.90, with a low of $325.35. The bullish earnings news and raised outlook suggest a positive direction, though the sharp price decline indicates market reaction may have been influenced by other factors.
Critical news
Nov 4HIGHEarnings: growth/beat

Thesis

  • •Revenue growing -0.8% YoY with SLOWING trend — consistent growth.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CRL.

Start Free Trial →

Is CRL Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

P/E Forward, P/B, PEG, Analyst Consensus

Fair Value

$1277.76

14

Moat Score

NONE

4/9

Piotroski Score

3.5

Altman Z-Score

What Is Smart Money Doing with CRL?

Insider Signal

SELLING

0 buys / 6 sells (90d)

Congress Signal

BUYING

3 buys / 2 sells (90d)

Institutional

N/A

Short Squeeze Risk

MEDIUM

Signal: NEUTRAL

Recent Insider Activity

NameTitleTypeSharesValueDate
Parisotto Shannon MofficerBuy2,156$527KOct 21, 2026
Parisotto Shannon MofficerSale2,156$743KOct 21, 2026
Parisotto Shannon MofficerBuy981$204KOct 5, 2026
Parisotto Shannon MofficerSale981$303KOct 5, 2026
FOSTER JAMES CdirectorBuy21,132$4.1MAug 25, 2026
FOSTER JAMES CdirectorBuy12,429$2.6MAug 25, 2026
FOSTER JAMES CdirectorSale33,561$10.1MAug 25, 2026
Girshick Birgitdirector officerSale528-Aug 19, 2026
Parisotto Shannon MofficerBuy2,039$396KAug 19, 2026
Parisotto Shannon MofficerSale2,039$600KAug 19, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

CRL Growth Story

Revenue YoY

-0.8%

3yr Revenue CAGR

0.3%

EPS Growth YoY

-1555%

FCF Growth YoY

3.4%

Revenue Trend

SLOWING

Dark Pool Trades for CRL

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for CRL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

TimePriceSizeValueSide
19:12:06$339.931,000$$340KSELL
18:38:21$338.181,040$$352KSELL
17:11:21$335.971,755$$590KSELL
17:10:22$336.053,471$$1.2MBUY
16:15:47$334.7712,806$$4.3MBUY

5 dark pool trades shown · $$6.7M preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Options Flow for CRL

PREVIEW

SEPT Investing provides real-time options flow tracking for CRL, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.

TypeStrikeExpiryDTEPremiumSizeTrade
PUT$350Nov 207$$18601SWEEP
PUT$350Nov 207$$18601SWEEP
PUT$350Nov 207$$37202SWEEP
PUT$350Nov 207$$37202SWEEP
PUT$350Nov 207$$18501SWEEP

5 options trades shown · 0% calls

Unusual activity, GEX levels, max pain, and dealer positioning

See full options flow

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

Sign Up Free — Download AI Report PDF →

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

Compare SEPT with other platforms

SEPT vs TradingViewSEPT vs BloombergSEPT vs Unusual WhalesSEPT vs SpotGammaSEPT vs TrendSpiderAI Trading Platforms Compared
What is dark pool trading?How to read options flowGEX explainedSmart money trackingAI stock analysisEarn money on SEPT

About SEPT Investing

SEPT Investing tracks 13,000+ stocks with live charts, trend and key-level tracking, dark pool and options flow, insider and congress trades, SEC filings and news alerts.

Disclaimer: This page is for informational purposes only. It does not constitute financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.

CRL — frequently asked questions

What is CRL stock price today?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is at $339.77, down 0.31% (-$1.04) at the Nov 13, 2026 close.

Why is CRL stock moving today?

Latest CRL news — Nov 13, 2026: Banca Akros raises Carel Industries rating to Buy · Nov 13, 2026: Intermonte raises price target for Carel Industries

Why did CRL stock move on Nov 4, 2026?

Charles River Laboratories reported third-quarter 2026 adjusted earnings of $3.09 per share and revenue of $982.732 million, both beating analyst estimates of $2.97 and $958.693 million, and raised its full-year 2026 adjusted EPS guidance to $11.35-$11.55 and sales to $3.940B-$3.960B, above consensus. The company also lifted its FY2026 GAAP EPS outlook to $8.15-$8.35 from $3.05-$3.35.

What is the CRL price target?

The average analyst price target for CRL is $340.00, ranging from $219 to $400, based on 13 analysts.

What do analysts rate CRL?

Analyst ratings for CRL: 3 Buy, 23 Hold, 0 Sell — consensus Hold.

Did CRL beat earnings?

CRL last reported on Nov 4, 2026: EPS $3.09 vs $2.97 expected — a beat of 4.0%.

What is CRL's P/E ratio?

CRL trades at a P/E of 355.0 vs a Healthcare average of 17.4.

Does CRL pay a dividend?

CRL does not currently pay a dividend.

How much debt does CRL have?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported $2.4B of debt and $200M of cash (Sep 26, 2026).

What are CRL support and resistance levels?

Support: $333.30, $311.68, $288.43. Resistance: $358.76, $379.63.

What are insiders doing with CRL?

Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.

What is the latest news on CRL?

Nov 13, 2026: Banca Akros raises Carel Industries rating to Buy · Nov 13, 2026: Intermonte raises price target for Carel Industries · Nov 12, 2026: Charles River Laboratories, Toxys Broaden Existing Partnership